BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19236381)

  • 1. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.
    Montopoli M; Ragazzi E; Froldi G; Caparrotta L
    Cell Prolif; 2009 Apr; 42(2):195-206. PubMed ID: 19236381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
    Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines.
    Baharuddin P; Satar N; Fakiruddin KS; Zakaria N; Lim MN; Yusoff NM; Zakaria Z; Yahaya BH
    Oncol Rep; 2016 Jan; 35(1):13-25. PubMed ID: 26531053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
    Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
    Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.
    Weir NM; Selvendiran K; Kutala VK; Tong L; Vishwanath S; Rajaram M; Tridandapani S; Anant S; Kuppusamy P
    Cancer Biol Ther; 2007 Feb; 6(2):178-84. PubMed ID: 17218783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Marverti G; Ligabue A; Montanari M; Guerrieri D; Cusumano M; Di Pietro ML; Troiano L; Di Vono E; Iotti S; Farruggia G; Wolf F; Monti MG; Frassineti C
    Invest New Drugs; 2011 Feb; 29(1):73-86. PubMed ID: 19834646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.
    Zheng H; Hu W; Yu D; Shen DY; Fu S; Kavanagh JJ; Wei IC; Yang DJ
    Pharm Res; 2008 Oct; 25(10):2272-82. PubMed ID: 18509599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
    Hector S; Nava ME; Clark K; Murphy M; Pendyala L
    Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.